Technology
Health
Biotechnology

Concert Pharmaceuticals

$10.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-1.65%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell CNCE and other stocks, options, ETFs, and crypto commission-free!

About CNCE

Concert Pharmaceuticals, Inc. Common Stock, also called Concert Pharmaceuticals, is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Read More Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Employees
71
Headquarters
Lexington, Massachusetts
Founded
2006
Market Cap
255.39M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
115.93K
High Today
$10.94
Low Today
$10.70
Open Price
$10.92
Volume
71.71K
52 Week High
$17.86
52 Week Low
$9.21

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO
US

CNCE Earnings

-$0.93
-$0.68
-$0.44
-$0.19
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.